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Abstract
Data on the elderly population with inflammatory bowel dis-
ease (IBD) are scarce, as this population is normally excluded 
from clinical trials. With an ageing population and an overall 
increasing prevalence of IBD; the incidence of IBD in elderly 
is rising. Comorbidities, wide differential diagnosis and poly-
pharmacy make the diagnosis and management of the dis-
ease in elderly more challenging compared to that in young-
er adults. The knowledge of specific requirements for the 
management and treatment of IBD in advanced age may 
help in the framing of the definition of the appropriate care 
of this patient group. This manuscript reviews the most re-
cent knowledge in the epidemiology, diagnosis and man-
agement of IBD in this population. © 2018 S. Karger AG, Basel
Introduction
Age at the onset of inflammatory bowel disease (IBD) 
ranges from early childhood to beyond the seventh de-
cade of life. Irrespective of the age at the time of diagnosis, 
IBD is relatively common in elderly individuals due to the 
chronic nature of the disease [1].
There is often a delay in achieving a correct diagnosis 
in elderly IBD due to the number of IBD-like symptoms 
that overlap with the symptoms of other diseases [2]. Be-
cause it takes a long time to make a diagnosis in the el-
derly population, the probability that prompt optimised 
disease management strategies are implemented from the 
very early stage of the disease gets reduced. The increased 
rate of misdiagnosis with advanced age [3], the presence 
of comorbidities and prevalence of polypharmacy in el-
derly subjects also greatly contribute to worsening the 
treatment outcome. 
The elderly population with IBD is poorly represented 
in clinical trials [4], as many trials exclude individuals 
aged > 65 years. This results in a relatively poor evidence 
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base to guide appropriate therapeutic management deci-
sions in this population. The risk of treatment-related ad-
verse effects, as well as of surgical complications, may in-
crease with advanced age, thus emphasizing the need for 
good quality clinical data on which to base decisions [5]. 
The present review summarises the disease characteris-
tics, the clinical presentation, the methods of evaluating 
and monitoring IBD and the specific challenges faced by 
elderly patients in terms of selecting the most appropriate 
disease management strategy.
Epidemiology
Currently, there is no accepted universal definition of 
the term “elderly.” Although “elderly” is often defined as 
those with chronological age 65 years or older in most 
developed countries, there is still some discrepancy in 
terms of the threshold value from a healthcare perspec-
tive, given that other markers of old age, such as the gen-
eral health state or the presence of concomitant diseases, 
may influence the physical mark of old age. 
Previously published reviews on IBD in the elderly 
have set a threshold value of 60 years of age [3, 4, 6, 7], 
whereas the age of 65 years has been fixed as a reference 
value for the definition of elderly in other reports [1, 8, 9]. 
Irrespective of the definition, the incidence and preva-
lence of IBD in the elderly are on the rise as a consequence 
of the ageing population. The evidence that IBD has rela-
tively little effect on lifespan further contributes to the in-
crease in the number of individuals aged > 65 years living 
with IBD [8]. This increasing trend is more evident in high-
income than in low-income countries, but the process of 
urbanisation, improved diagnostic methods and disease 
awareness have contributed to an increased IBD prevalence 
and incidence in regions such as Asia and the Middle East 
[10]. Thus, it is expected that the increase in the incidence 
of IBD diagnosed in advanced age will continue to further 
increase in the next decades on a worldwide basis [1]. 
Despite some variability of data across epidemiologi-
cal studies due to regional differences and methods of di-
agnosis, the incidence rates of ulcerative colitis (UC) in 
the elderly are higher than those for Crohn’s disease (CD) 
and range from 1 to 20/100,000 for UC in Europe and in 
the United States [6] compared to 1 to 10/100,000 for CD 
in Europe [1, 6]. A recently published National cohort 
study in Sweden has reported that 23% of subjects with di-
agnosed IBD had a first diagnosis of IBD at age ≥60 years 
and that in elderly patients, the IBD incident rate was 
35/100,000 person/years (male: 37; female: 33) and was 
10/100,000 for CD, 19/100,000 for UC, and 5/100,000 for 
IBD unclassified [11]. 
Irrespective of the age at diagnosis, epidemiological 
studies have estimated that about 25–35% of individuals 
with IBD are > 60 years of age [6]. 
Diagnosis
There are 2 distinct groups of elderly patients with 
IBD: those who have had IBD for several decades and 
those who have received a diagnosis later on in life (elder-
ly-onset IBD) [4]. Overall, it is estimated that up to 15% 
of patients have been diagnosed after the age of 60 years, 
while up to 20% of these patients have been diagnosed 
earlier and have transitioned into older age [4, 6]. In the 
previously mentioned National cohort study in Sweden 
[11], more than 1 out of 5 incidents of CD (21%) and UC 
(24%) cases occurred in elderly individuals. Notably, new 
diagnoses of UC are generally more common in elderly 
males than in females, with reversed rates for newly diag-
nosed CD [8]. 
Time to Diagnosis is Longer in the Elderly
Compared to younger adults, the initial diagnosis of 
IBD in the elderly is generally more difficult and conse-
quently of longer duration. On average, there is a delay 
in diagnosis of up to 6 years in the elderly compared to 
2 years in younger adults [3]. This is partly due to misdi-
agnosis: an initial incorrect diagnosis of CD was reported 
in 51 and 39% of elderly and younger patients respective-
ly [12]. Factors that may account for this difference in-
clude access to specialist healthcare and the prevalence of 
conditions mimicking IBD, giving a wider differential di-
agnosis [1]. Delay in diagnosis may have a negative im-
pact on disease outcome in terms of overall complications 
and progression to a stricturing and/or a penetrating dis-
ease, with a consequent increase in need for surgery [13].
Clinical Characteristics of IBD in Elderly
It is acknowledged that the natural history of elderly-
onset IBD is less aggressive as compared to younger pa-
tients [14–16]. Elderly patients with CD have more co-
lonic involvement with lower frequency of strictures and 
fistulas as compared to younger individuals, while elderly 
UC patients experience more commonly left-sided or ex-
tensive colitis vs. proctitis. Furthermore, in UC patients, 
the disease location tends to remain stable, with only 16% 
of individuals showing proximal disease extension at 
 follow-up visit [15].
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Although the clinical presentation of the disease dif-
fers frequently between elderly and younger individuals, 
age-related differences in clinical presentation are more 
evident in CD patients than in UC patients. Compared to 
younger adults, CD diagnosed in advanced age presents 
more often with rectal bleeding and less often with diar-
rhoea, abdominal pain and weight loss [4]. Conversely, 
the severity of symptoms of UC (especially rectal bleeding 
and diarrhoea) is usually milder in elderly than that in 
younger individuals, and the presentation in the elderly 
may be atypical [7].
As demonstrated in the EPIMAD study, elderly-onset 
CD subjects report less abdominal pain, systemic symp-
toms and diarrhoea, while subjects with a diagnosis of UC 
in older age report less abdominal pain and rectal bleed-
ing [17]. 
More evident differences between elderly and younger 
adults emerge during the endoscopic examination and 
(to a lesser extent) from histopathology. Generally, the 
presence of isolated colonic inflammation with less fre-
quent penetrating or perianal disease is a more common 
finding in elderly-onset CD and small bowel and upper 
gastrointestinal disease is less common [4, 15]. 
Because of phenotype-related differences and the pres-
ence of comorbidities, the management of IBD in the el-
derly may be different as compared to that of younger 
patients [14].
Differential Diagnosis
Differential diagnosis is one of the most important 
challenges for disease management, especially in older 
subjects. Several other diseases (such as ischemic colitis, 
motility disorders, drug side effects etc.) present clinical 
characteristics that may in part overlap with those of IBD. 
This may cause the above-mentioned delay in establish-
ing the correct diagnostic process, or an incorrect diag-
nosis, which ultimately may lead to inappropriate thera-
py. Table 1 lists the most relevant differential diagnoses 
of IBD in the elderly.
Management of the Disease in the Elderly
Challenges in the Management of IBD 
Comorbidities, Polypharmacy and Treatment 
Compliance
Comorbid health conditions such as heart disease, di-
abetes, cancer, psychiatric disorders and arthritis are 
commonly present in elderly patients with IBD [15]. This 
contributes to a higher risk of complications and mortal-
ity after a severe attack of UC or CD in advanced age [18]. 
Furthermore, polypharmacy has the potential to increase 
the risk of drug interactions, and drugs used in the treat-
ment of IBD may contribute to either triggering or wors-
ening concomitant diseases as is the case of diabetes or 
psychiatric disorders with steroid-based therapy, heart 
failure with anti-tumor necrosis factor (anti-TNF) mono-
clonal antibodies and cancer with immunomodulators 
(including lymphoma with thiopurines). This may lead to 
poorer prognosis and an increased risk of IBD-related 
complications. 
Poor Adherence to Therapies is Common in IBD and 
is More Evident in the Elderly
The concurrent administration of multiple drugs in a 
significant proportion of elderly IBD patients further 
contributes to reduce the adherence to the prescribed 
therapy, and hence to worsen the course not only of the 
IBD, but also of the other comorbidities. The use of sim-
plified once-daily medication regimens and the avoid-
ance of unnecessary multiple concomitant medications 
may be associated with improved adherence to therapy 
and clinical outcome [19].
Treatment Goals and Therapeutic 
Approaches – Differences with the General Population
Evolution of Treatment Goals in IBD: Clinical 
Remission and Mucosal Healing
Treatment goals in IBD have been reviewed in recent 
years. The primary goal has evolved from achieving clin-
ical remission towards the induction and maintenance of 
both clinical and endoscopic remission (i.e., mucosal 
healing), that is, the so-called deep remission. The evi-
dence-based consensus from the European Crohn’s and 
Colitis Organisation highlighted the importance of the 
evaluation of endoscopic mucosal inflammation even in 
the case of maintenance of symptom control, as mucosal 
healing correlates with reduced hospitalisation and sur-
geries [20].
Patient-Reported Outcomes 
Patient-reported outcomes (PROs) have shown to of-
fer important advantages over other more complicated 
composite endpoints, such as the CD Activity Index. 
PROs involve patients in the evaluation and in the man-
agement of their disease, as well as in sharing the manage-
ment strategy with their physician. However, the patient 
perspective does not necessarily correlate with that of the 
physician, as physicians often tend to report fewer and 
milder symptoms than patients [21]. This may underes-
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timate the severity of the problem or may overestimate 
treatment improvement, while at the same time minimis-
ing potential drug-induced adverse effects. Thus, the use 
of simple patient-generated items derived from more 
complex instruments may be a valid tool to be used in 
clinical trials for the development of new drugs and for 
patient-driven clinical care. Simple 2-item PROs (PRO-2) 
derived from the CD Activity Index, such as the resolu-
tion of abdominal pain (abdominal pain ≤1) and the nor-
malisation of bowel habit (mean daily stool frequency 
≤1.5), have been shown to be appropriate for use in clin-
ical trials in CD patients [22]. Similarly, a PRO-2 derived 
from the Mayo score consisting of resolution of rectal 
bleeding (score = 0) and normalisation of bowel habit 
(stool frequency ≤1) proved to be an appropriate measure 
in UC patients [23].
Although PROs have become important tools in the 
management of IBD, they have several limitations. 
First, PROs need to be validated over a complex process 
and not all PROs are currently validated for entering 
routine use in clinical trials or in clinical practice. Fur-
thermore, PROs are generally based on subjective eval-
uation of symptoms: to not limit assessment to subjec-
tive components only, clinicians may tend to combine 
patient’s evaluation of symptoms with the objective as-
sessment of inflammation and disease severity based on 
laboratory markers and endoscopy. Finally, the use of 
PRO-2 as a primary endpoint in clinical trials will make 
comparison with older historical trials difficult. As the 
development and validation of PROs is derived from 
randomised clinical trials, from which elderly patients 
are generally excluded, there is little or no information 
Table 1. Differential diagnosis of inflammatory bowel disease (IBD; modified from [1, 4, 6])
Disease Clinical characteristics Distinguishing findings 
Infectious
gastroenteritis/
colitis 
Acute onset of diarrhoea
with possible blood,
fever, dysentery 
Recent use of antibiotics, positive stool samples for 
 pathogen agents (e.g., Clostridium difficile), 
 pseudomembranes on endoscopy with Clostridium difficile, 
positive stool studies, rapid resolution with appropriate 
antibiotic therapy 
NSAID-induced 
colitis 
Diarrhoea with possible
blood, abdominal pain, iron deficiency
anaemia, obstruction, perforation 
History of chronic NSAIDs use, diaphragm-like
small bowel stricture, isolated lesions, any part of the
intestine may be affected, exacerbate existing
ulcerative colitis (UC) or Crohn’s disease (CD)
Ischaemic colitis Acute onset of  abdominal
pain followed by bloody
diarrhoea, association with food intake 
Segmental area of injury, rectal sparing, typical
sigmoid/left sided colitis, rectum sparing, abrupt
transition between normal and affected mucosa,
possible concomitant cardiovascular disease
Segmental colitis 
associated with 
diverticulosis
Bloody stools, diarrhoea, abdominal pain History of diverticular disease, local inflammation in and 
around diverticulum only at endoscopy, rectum and 
 proximal colon spared
Radiation colitis Bloody diarrhoea, abdominal pain,
urgency, tenesmus, symptoms occur
weeks to years after abdominal/pelvic radiation 
History of abdominal or pelvic radiation, histological 
 fibrosis and capillary telangiectasia (i.e., different findings 
from IBD)
Microscopic colitis Non-bloody diarrhoea, predominant
in females
No anatomical abnormalities visible at endoscopy, 
 histologically different from IBD
Diversion colitis Occurs in surgically diverted bowel loop,
most asymptomatic but can haveabdominal
pain and bloody/mucous discharge
Histologically, prominent lymphoid hyperplasia 
Solitary rectal
ulcer syndrome
Bloody diarrhoea with straining, rectal
bleeding, straining, pelvic fullness
History of constipation, histologically thickened
mucosal layer and crypt architectural distortion, smooth 
muscle and collagen replace lamina propria (i.e., different 
findings from IBD)
NSAID, non-steroidal anti-inflammatory drugs.
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on the appropriateness and validity of use of PROs in 
advanced age. Furthermore, PROs reporting may vary 
according to age range, and other factors, such as con-
comitant diseases or mood disturbances, which may af-
fect the patient perception of subjective symptoms in 
older individuals.
Faecal Calprotectin and C-Reactive Protein
In addition to clinical and endoscopic evaluations, the 
determination of biomarker levels, such as C-reactive 
protein (CRP) and faecal calprotectin (FC) is useful for 
measuring disease activity in a non-invasive way and 
driving therapeutic decisions.
FC has been shown to be a reliable marker for assess-
ing IBD disease activity [24] and in predicting mucosal 
healing and risk of relapse in CD patients [25–27]. CRP 
was also found to be a predictor of surgery in subgroups 
of patients with either UC or CD [28]. There is evidence 
that FC is superior to CRP in the prediction of clinical 
response and mucosal healing in IBD patients [29, 30]. 
There are scarce data on the predictive role of bio-
markers in older individuals. Circulating levels of bio-
markers in the elderly may be affected by complicating 
factors, such as the effects of comorbidities on CRP con-
centration. Moreover, several differential diagnoses with 
increased prevalence in older individuals (e.g., Clostridi-
um difficile infection or ischaemic colitis) may be misin-
terpreted as a flare as they induce FC. For these reasons, 
research limited to elderly population is needed to better 
elucidate the value of non-invasive biomarkers in pre-
dicting the course of the disease.
Medical Therapy: Therapeutic Approaches 
Step-Up versus Top-Down Approach
Different approaches that have been established in 
younger patients may also be used in the management of 
elderly IBD patients. Generally, a step-up approach, in 
which a conventional therapy is added if first-line treat-
ment is ineffective, has been preferred for many years. As 
an example, oral/topical mesalazine and/or topical corti-
costeroids are generally used as starting therapy for mild 
to moderate UC, whereas systemic corticosteroids and 
biologicals (with azathioprine given during remission) 
are more often used in moderate/severe forms. However, 
studies have shown that a top-down approach, in which 
a potent agent is started at the early stage of the disease, 
such as an aggressive treatment with anti-TNF alpha 
agents, may be associated with reduced hospitalisation 
and surgeries in CD patients, which compensate the low-
er cost of traditional therapies, and with reduced risk of 
immunogenicity and associated infusion reactions. Thus, 
the to-down approach may offer the potential advantage 
of achieving disease stabilisation and minimising compli-
cations leading to surgery, while at the same time reduc-
ing the risk of adverse effects of corticosteroid therapy 
[31]. The current guidelines do not suggest differences 
between elderly and younger patients in the management 
of IBD. Therefore, the choice of the most appropriate 
therapeutic approach in older patients should be driven 
by balancing potential benefits and risks on an individual 
basis. Indeed, the increased risk in the use of drugs such 
azathioprine (e.g., lymphoma) or anti-TNF alpha agents 
(infections) should be evaluated taking into consider-
ation the fact that refraining from these drugs may induce 
an underuse and increased risk of surgery. 
Treat to Target (STRIDE Recommendations)
In the view of the limitations posed by the classical 
step-wise treatment intensification with re-evaluation of 
response according to symptoms, that is, the risk of un-
der-treatment and of delay of highly effective therapy, a 
treat-to-target algorithm has been recently developed 
based on an evidence-based expert consensus process [32, 
33]. The implementation of such strategy requires the 
definition of reliable targets (e.g., clinical/PRO remis-
sion) and the intensification of repeated tests (e.g., colo-
noscopy) with respect to the standard schedule used in 
clinical practice. 
This approach may offer several advantages. First, it 
improves and accelerates treatment decisions by mini-
mising the delay between changes in therapy. Then, treat-
ment is intensified or de-escalated as appropriate accord-
ing to each individual requirement. Most importantly, by 
identifying patients with a poor prognosis or at risk of 
relapse, this approach contributes to improve patient out-
comes. Ultimately, the use of a treat-to-target algorithm 
has the potential to change the progressive course of IBD. 
The most recent evidence of the advantages of this ap-
proach comes from the results of the completed CALM 
trial [34], which has showed that adjusting biologic ther-
apy using tight monitoring and a treat-to-target strategy 
to normalise FC and CRP led to higher endoscopy healing 
rates and deep remission rates than just treating clinical 
symptoms.
Again, the lack of trials specifically conducted in the 
elderly population and the awareness that the evidence- 
and consensus-based recommendations on potential 
treatment targets for IBD is based on the review of sys-
tematic literature that largely excludes older individuals, 
does not lead to the understanding whether and to which 
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extent the use of a treat-to-target approach may help in 
the management of IBD in elderly. It should also be con-
sidered that the use of frequent colonoscopies for the as-
sessment of endoscopic remission in elderly and comor-
bid patients might be inappropriate, and that the pres-
ence of comorbidities may also make physicians less 
willing to investigate fully. This may also contribute to a 
delay in diagnosis.
Hospital Admission and Mortality: Tailored 
Treatment to Avoid Admission
IBD is associated with significant rates of patients un-
dergoing surgery. The lifetime risk of surgery has been 
estimated to reach 70–80% for CD and 20–30% in UC, 
although rates for surgery vary between countries and re-
gions [35]. Recent studies suggest that mortality rates in 
IBD patients seem higher than previously estimated, and 
there are emerging threats to mortality. In fact, the post-
operative mortality accounts only for a small proportion 
of death in IBD patients, and other emerging new threats, 
such as Clostridium difficile infection, malignancy, cere-
brovascular disease, thrombosis and adverse effects of 
medical treatment, may contribute to increased risk of 
deaths [36]. 
Elderly IBD patients have more frequent hospital ad-
missions and may have substantially higher postoperative 
mortality and more complications than younger patients 
[11, 37]. In particular, the risk of thrombotic complica-
tions of IBD during hospitalisation is increased in elderly 
IBD patients as a consequence of disease-related hyper-
coagulability, reduced mobility and dehydration [1].
Specific Therapeutic Considerations
Although the available drugs for the treatment of IBD 
in the elderly are the same as those used in younger pa-
tients and the effects of medical therapy are not related 
with age, the speed of response may be slower in advanced 
age, and there are several therapy-specific factors that 
may increase the risk of unfavourable outcome in elderly 
IBD patients [8]. Table 2 summarises the potential drug-
drug interactions for 5-ASA derivatives, corticosteroids 
and immunomodulators, which should be taken as refer-
ence prior to considering the choice of therapy in elderly 
IBD patients, as they can affect the efficacy and safety of 
treatments for both IBD and comorbidities. 
Therapies prescribed to elderly often differ from those 
used in younger subjects. A retrospective study conduct-
ed in the US has shown that ≥40 and 35% of elderly pa-
Table 2. Summary of drug-drug interaction for 5-aminosalicylic acid (5-ASA/mesalazine) derivatives, corticosteroids and immunomod-
ulators
Drug class Interactions
5-ASA derivatives 5-ASA increases the anticoagulant activity of warfarin
5-ASA increases the risk of leukopenia if used in combination with thiopurines
Mesalazine reduces serum concentration (and efficacy) of digoxin
Mesalazine increases serum concentration (and the risk of adverse effects) of hydralazine and second 
generation of anti-tuberculosis drugs
5-ASA concentration increases if used with methotrexate
Corticosteroids The efficacy of corticosteroids is reduced (due to increased clearance) with use of anti-epileptics
Corticosteroids may increase the anticoagulant activity of warfarin
Corticosteroids may reduce the effects of antidiabetic agents
The use of calcium channel blockers may increase the serum concentration (and the risk of adverse 
effects) of corticosteroids
Corticosteroids may increase the hypokalaemic effects of diuretics
Immunomodulators Thiopurines reduce the anticoagulant activity of warfarin
Thiopurines increase the risk of myelotoxicity if used with allopurinol (due to its xanthine
oxidase-mediated action)
Thiopurines increases the risk of leukopenia if used in combination with 5-ASA, clotrimazole
and angiotensin-converting enzyme inhibitors
Methotrexate concentration increases if used with 5-ASA derivatives, NSAIDs,
penicillin’s or tetracyclines
Methotrexate may increase levels of theophyllines
Methotrexate may alter the concentration of loop diuretics and vice-versa
Azathioprine increases the effect of coumarin derivatives
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tients use IBD maintenance treatment with 5-ASA and 
corticosteroids, respectively, compared to a low utilisa-
tion of immunomodulator and biologic agents. On aver-
age, elderly patients with IBD used a mean number of 
7 concomitant drugs [38]. 
Although the use of each drug class is associated with 
its own specific risks, advanced age and the presence of 
comorbidities are risk factors for infections in IBD pa-
tients, irrespective of the type of treatment. The increased 
risk of infections, which is specific for each immunosup-
pressant drug, appears to be the most relevant age-specif-
ic feature to be taken into consideration. The lack of clin-
ical trials investigating the effects of immunomodulators 
for the management of IBD in the elderly does not allow 
a reliable quantification of this risk. 
Although its risk-benefit ratio should be evaluated in 
randomised clinical trials, there is recent evidence that leu-
kocyte apheresis, an extracorporeal therapy that produces 
anti-inflammatory effects by removing activates leuko-
cytes or platelets from peripheral blood, may be a safe and 
effective therapeutic option for UC in the elderly. In par-
ticular, the rate of adverse effects related to infections fol-
lowing leukocyte apheresis is generally low and similar in 
younger and elderly UC patients [39]. The potential ad-
vantages of this therapy in terms of safety should be bal-
anced against the length of time required for the procedure 
and hence the potential delay of intensified treatment next 
to leukocyte apheresis if it was not effective.
5-Aminosalicylic Acid (5-ASA/Mesalazine)
5-ASAs are first-line treatment for the induction and 
maintenance of remission in mild to moderate UC, while 
they have no effect in CD. Overall, the elderly tend more 
likely to receive 5-ASA than immunomodulators and corti-
costeroids [8]. The efficacy of 5-ASA compounds is gener-
ally comparable in both younger and older patients and 
5-ASA is largely used in the elderly due to its acceptable 
safety profile. Although once-daily dosing and foam formu-
lations of topical therapy might increase compliance to 
therapy, adherence rates to 5-ASA are suboptimal in elder-
ly due to the lack of the necessary dexterity to administer 
enemas and/or oral forms, as well as due to the need to ad-
just the volume of enema formulations in case of the pres-
ence of faecal incontinence [9]. Important drug interactions 
of 5-ASA are reported with warfarin. The half-life of 5-ASA 
derivatives can be increased in the elderly due to a reduction 
in glomerular filtration and renal clearance. Due to this, the 
monitoring of renal function during 5-ASA therapy is re-
quired, especially in patients with pre-existing renal impair-
ment, or in the case of concomitant use of other potentially 
nephrotoxic drugs [38]. Other important interactions of 
mesalazine with drugs commonly used in the elderly in-
clude digoxin (reduced serum concentration and efficacy), 
hydralazine and the second generation of anti-tuberculosis 
drugs (increased serum concentration and risk of adverse 
effects) [9]. The availability of several 5-ASA formulations 
and the potential drug interaction profile highlight the im-
portance of optimising the formulation and administration 
based on the individual patient requirements.
Corticosteroids
Corticosteroids are used for the treatment of IBD be-
cause of their effectiveness in the management of acute 
symptoms. However, the use of corticosteroids in the treat-
ment of IBD in elderly people carries additional risks. The 
prolonged use of corticosteroids predisposes patients to 
cataracts and glaucoma, or precipitates/exacerbates pre-
existing conditions, such as diabetes, hypertension, osteo-
porosis or mental state alterations. The risk of fractures in 
the elderly is enhanced, as corticosteroid therapy is associ-
ated with malabsorption and malnutrition. Prolonged ste-
roid therapy increases the risk of infections (especially fun-
gal infections) and associated complications. The risk of 
gastrointestinal haemorrhage is also increased when corti-
costeroids are given in association with non-steroidal anti-
inflammatory drugs [9]. Moreover, ageing CD patients 
treated with steroids are at a significantly increased risk for 
developing hypokalaemia and mental status changes [40, 
41]. Due to these reasons, it has been estimated that only 
25–33% of elderly IBD patients are treated with corticoste-
roids [8], even though recent data from Sweden indicate 
these figures represent an underestimation of the cumula-
tive exposure to steroids [11]. Although budesonide seems 
to be a preferable option as it interferes less with bone me-
tabolism, repeated bone densitometry and vitamin D/cal-
cium supplementation are still required for the prevention 
of bone loss. Corticosteroids given in combination with 
other immunosuppressive agents increase the risk of seri-
ous infections [42]. Corticosteroid clearance is decreased in 
the elderly, which exposes patients to increased risk of cor-
ticosteroids-induced adverse effects. Modified-release for-
mulations of budesonide or the multi-matrix budesonide 
formulation are considered the first-line option for elderly 
population due to their improved safety profile, while re-
taining the anti-inflammatory properties of budesonide.
Immunomodulators
The response to immunomodulator therapy is the 
same in elderly patients and younger adults [7]. 6-mer-
captopurine or azathioprine is used in approximately 6% 
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of cases, with only 1% of patients receiving methotrexate 
[38]. This low use of immune-modifying agents is likely 
to be due to the risk of severe adverse effects and the re-
quirements for blood test monitoring, especially in elder-
ly patients. Known adverse events include leucopenia and 
transaminases increase, allergic reactions, mild (nausea 
and dyspepsia) or severe (acute pancreatitis) gastrointes-
tinal adverse effects, increased risk of or non-melanoma 
skin cancer. Adverse effects associated with the use of 
methotrexate include nausea, fatigue, stomatitis, rash 
and, most importantly, worsening of hypertension and 
renal insufficiency, which are common comorbidities in 
elderly subjects. The risk of non-Hodgkin’s lymphoma 
with thiopurines, especially when given in combina-
tion  with anti-TNF therapy, is also increased in males 
aged > 60 years [1, 4]. Compared with the expected rate of 
non-Hodgkin’s lymphoma in the general population, it 
has been estimated that thiopurine-treated subjects had a 
threefold increased risk [43].
Finally, as thiopurines have a large spectrum of drug-
interactions, their use in the elderly requires dose adjust-
ments [8]. As an example, 6-mercaptopurine and azathi-
oprine require dose reduction and monitoring of liver 
function when given in conjunction with allopurinol, as 
this is the case for methotrexate when used together with 
5-ASA derivatives [3]. Azathioprine increases the effect 
of coumarin derivatives, requiring close monitoring of 
the prothrombin time in case of co-administration [9]. 
Anti-TNF
The role of anti-TNF therapy in inducing clinical and 
histological remission and in decreasing rates of hospi-
talisation and surgery in moderate to severely active IBD 
patients has been established [1]. However, it has been es-
timated that anti-TNF agents are used as part of mainte-
nance therapy in less than 10% of older CD and only in 
1–2% of older UC patients due to the risk of adverse effects 
or complications [4, 11]. A recent observational retrospec-
tive study [44] has shown that elderly patients treated with 
anti-TNF have a significantly lower rate of short-term 
clinical response (68% in the elderly vs. 89% in younger 
patients) and a higher risk of severe adverse events than 
the younger patients receiving the same treatment. There 
is evidence derived from the use of this drug class in rheu-
matic diseases suggesting that there is a trend towards an 
increased risk of infections in subjects aged > 65 years [7]. 
This trend has been confirmed in a study conducted in 
Italy [45], in which IBD patients older than 65 years treat-
ed with TNF inhibitors had a higher rate of severe infec-
tions and mortality compared with younger patients or 
patients of the same age not receiving these agents. How-
ever, it should be taken into consideration that combina-
tion therapy or other treatments for comorbid conditions 
may contribute to this trend [7]. Other important adverse 
effects reported with the use of anti-TNF agents in elderly 
patients include exacerbation of congestive heart failure, 
dermatological reactions, infusion reactions and neuro-
logical sequelae [1, 4]. In general, monotherapy should be 
preferred in patients requiring anti-TNF therapy. 
Surgery
Taking into consideration that approximately 25% of 
IBD surgeries are performed in patients aged > 55 years, 
specific considerations for the elderly IBD population 
should be made for surgical therapy. 
The rate of elderly patients undergoing surgery is 
higher than that of younger adults for CD [11], whereas 
surgery rates for UC are less age-dependent [8]. Although 
surgical indications in older patients are the same as those 
for younger subjects [7], post-operative mortality and 
rates of complications are higher in the elderly than that 
in younger subjects [4]. 
Although toxic megacolon is a potentially fatal com-
plication of colonic inflammation, it is not an absolute 
indication for immediate colectomy. Time for surgery in 
toxic megacolon remains controversial, with advocates 
for early surgery to avoid further complication and ad-
vocates for timely medical treatment to avoid surgery 
complication. Epidemiological data on toxic megacolon 
are very scarce, with large studies dating back to 1980. It 
is therefore difficult to extrapolate the epidemiology of 
this complication in the elderly population. According 
to Autenrieth et al. [46], the epidemiology of toxic mega-
colon has shifted towards infection causes, particularly 
due to an increase of Clostridium difficile-associated 
colitis and possible use/abuse of antibiotics. A recent 
survey conducted in the United States concluded that 
elderly patients with UC are at increased risk for infec-
tious complications and postoperative venous thrombo-
embolism, and that the length of hospital stay was longer 
in elderly than in subjects aged < 65 years [47]. This evi-
dence has been confirmed in a recent large-population 
cohort study [48] that included 21,218 IBD subjects (ap-
proximately 12% of elderly-onset patients), which 
showed that elderly-onset UC patients were more likely 
to undergo surgery and that elderly-onset CD patients 
had a higher rate of IBD-specific mortality compared to 
those with younger-onset disease. Although there is 
some evidence to suggest a decrease in UC-related mor-
tality rates over the last decade, advanced age and co-
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morbidities are still significantly associated with 3-year 
mortality, thus suggesting that other age-related condi-
tions (e.g., comorbid state and polytherapy) further in-
crease the inherent risk [49].
The used surgical technique has little influence on 
post-operative outcome. In fact, restorative proctocolec-
tomy with ileal pouch-anal anastomosis continues to be 
the surgical technique of choice in UC patients and the 
pouch failure rates observed in older patients are similar 
to those reported in younger subjects. However, the el-
derly are more likely to need urgent colectomy, which is 
associated with an increased risk of mortality, particu-
larly in the presence of comorbidities. In fact, comorbid 
conditions play a major role in the increased post-opera-
tive risk in elderly IBD. A large database study [50] that 
examined the surgical outcome in more than 35,000 pa-
tients who underwent IBD-related operations showed 
that common comorbidities of elderly, such as congestive 
heart failure, thromboembolic disease and renal disease, 
were associated with a significant increase in mortality 
rate. The evidence of the increased risk of post-operative 
complications in elderly IBD patients suggest that pre-
existing comorbidities, nutritional status and general 
health condition should be carefully evaluated, possibly 
referring to a multidisciplinary care, prior to consider 
surgical options in elderly IBD patients. 
These findings indicate that a more optimised disease 
management should be advocated in elderly IBD patients 
to reduce postoperative risks and risk of mortality in gen-
eral. These increased risks need to be considered when 
deciding the most appropriate management strategy. At 
the same time, delaying surgery in elderly IBD patients in 
which surgical therapy is indicated increases the risk of 
poor outcome [6].
Conclusions
IBD is relatively common in elderly subjects, with up 
to 35% of patients with IBD aged ≥60 years. However, 
clinical data on the characteristics and the outcome of the 
disease in advanced age are scarce.
Management of IBD in the elderly poses specific chal-
lenges. Diagnosis takes longer and misdiagnosis is also 
more common. Several diseases may mimic the clinical 
presentation of IBD and accurate differentiation is needed 
for appropriate management. Treatment of IBD in this 
special population is complicated by the presence of co-
morbidities and by the risk of drug interactions, which is 
exacerbated by polypharmacy. Cognitive decline and psy-
chiatric diseases, which are relatively common in elderly, 
further contribute to decreased adherence to therapy. 
Improving communication between the patient and 
the physician in decisions on the choice of the most suit-
able approach may allow for rapid implementation of the 
most appropriate disease management on an individual 
basis. Further studies specifically limited to the elderly 
population would help greatly to increase the knowledge 
of the characteristics of the disease in advancing age and 
hence to better define the diagnostic process and the ther-
apeutic strategy.
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